Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
The Maire - EuroChem Case: Three Lessons for Global Business 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
NEW YORK, May 18, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) who purchased shares between August 12, 2014 and April 28, 2017. The action, which was filed in the USDC for the Eastern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
Shareholders have until July 11, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/intra-cellular-therapies-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
